Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan NV Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,015,468
  • Shares Outstanding, K 515,631
  • Annual Sales, $ 11,908 M
  • Annual Income, $ 696,000 K
  • 36-Month Beta 1.63
  • Price/Sales 1.40
  • Price/Cash Flow 3.99
  • Price/Book 1.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.33
  • Number of Estimates 6
  • High Estimate 1.49
  • Low Estimate 1.22
  • Prior Year 1.43
  • Growth Rate Est. (year over year) -6.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.76 +11.89%
on 01/24/19
32.23 -3.63%
on 02/20/19
+1.47 (+4.97%)
since 01/18/19
3-Month
26.03 +19.30%
on 12/24/18
34.46 -9.87%
on 12/03/18
-2.32 (-6.95%)
since 11/21/18
52-Week
26.03 +19.30%
on 12/24/18
44.18 -29.70%
on 03/06/18
-10.15 (-24.63%)
since 02/21/18

Most Recent Stories

More News
Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, a generic version of Indivior's Suboxone®...

MYL : 31.06 (-1.77%)
Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Primary Progressive Multiple Sclerosis and New Treatments for MS

Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its GA Depot, a novel long-acting depot formulation...

MYL : 31.06 (-1.77%)
MAPI : N/A (unch)
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.

MYL : 31.06 (-1.77%)
JAZZ : 125.21 (-1.24%)
TEVA : 17.25 (-0.86%)
MNK : 20.52 (-3.30%)
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.

MYL : 31.06 (-1.77%)
BDSI : 4.73 (-0.63%)
ACOR : 13.38 (+2.14%)
SNSS : 0.53 (-3.64%)
Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.

MYL : 31.06 (-1.77%)
IRWD : 14.18 (-0.84%)
AZN : 40.43 (-0.25%)
AGN : 136.60 (-2.66%)
Mylan Launches Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand

Mylan N.V. (NASDAQ: MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of ADVAIR DISKUS®, Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol...

MYL : 31.06 (-1.77%)
Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2018 financial results, as well as its 2019 financial guidance, on Tuesday,...

MYL : 31.06 (-1.77%)
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

MYL : 31.06 (-1.77%)
LLY : 122.72 (+0.05%)
TEVA : 17.25 (-0.86%)
MNK : 20.52 (-3.30%)
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

MYL : 31.06 (-1.77%)
NVS : 90.51 (-0.25%)
PFE : 42.14 (-0.14%)
GSK : 40.54 (-1.98%)
Mylan's Generic Version of Advair Diskus Wins FDA Approval

Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.

MYL : 31.06 (-1.77%)
NVS : 90.51 (-0.25%)
MNK : 20.52 (-3.30%)
GSK : 40.54 (-1.98%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade MYL with:

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 32.08
1st Resistance Point 31.57
Last Price 31.06
1st Support Level 30.72
2nd Support Level 30.39

See More

52-Week High 44.18
Fibonacci 61.8% 37.25
Fibonacci 50% 35.11
Fibonacci 38.2% 32.97
Last Price 31.06
52-Week Low 26.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar